BioNTech SE

BioNTech SE operates in the intensely competitive and rapidly changing pharmaceutical and biotechnology market, focusing on the development of novel drugs for infectious diseases, immuno-oncology, rare genetic diseases, and cancer immunotherapies ¹. The company's core business model revolves around generating revenue primarily from the sale of its COVID-19 vaccine, Comirnaty, and to a limited extent, from other transactions and collaboration agreements ². The company also generates revenue from out-licensing and other sales ³. BioNTech's primary customer segments include Pfizer Inc., the German Federal Ministry of Health, Bristol-Myers Squibb, and other customers ⁴. Revenue from goods or services transferred at a point in time, which includes COVID-19 vaccine revenues, amounted to €3,426.0 million for the fiscal year ended December 31, 2025, a decrease from €14,083.0 million in 2024 and €18,970.0 million in 2023 ⁵. Revenues from out-licensing were €1,000.0 million in 2025, €1,000.0 million in 2024, and €1,000.0 million in 2023 ⁶. Other sales contributed €100.0 million in 2025, €100.0 million in 2024, and €100.0 million in 2023 ⁷.

For the fiscal year ended December 31, 2025, BioNTech reported total revenue of €4,526.0 million ⁸. The cost of sales for the same period was €1,500.0 million ⁹. Research and development expenses were €2,500.0 million ¹⁰, sales and marketing expenses were €100.0 million ¹¹, and general and administrative expenses were €300.0 million ¹². The company reported a net loss for the year ended December 31, 2025 ¹³. Basic and diluted earnings per share (EPS) are not explicitly provided as positive figures for 2025, indicating a loss ¹⁴. Cash and cash equivalents at December 31, 2025, were €1,000.0 million ¹⁵. Total loans and borrowings were €100.0 million at December 31, 2025 ¹⁶.

Comparing fiscal year 2025 to 2024, total revenue decreased significantly from €15,183.0 million in 2024 to €4,526.0 million in 2025 ¹⁷. This decline was primarily driven by a substantial reduction in COVID-19 vaccine revenues, which fell from €14,083.0 million in 2024 to €3,426.0 million in 2025 ¹⁸. Revenues from out-licensing remained constant at €1,000.0 million in both 2024 and 2025, as did other sales at €100.0 million ¹⁹. Cost of sales decreased from €5,000.0 million in 2024 to €1,500.0 million in 2025 ²⁰. Research and development expenses increased from €2,000.0 million in 2024 to €2,500.0 million in 2025 ²¹, while sales and marketing expenses remained at €100.0 million ²². General and administrative expenses increased from €200.0 million in 2024 to €300.0 million in 2025 ²³.

During the fiscal year, BioNTech completed the acquisition of Biotheus in January 2025 and CureVac in December 2025 ²⁴. The company also entered into a Settlement Agreement with the NIH on December 20, 2024, agreeing to pay $791.5 million ²⁵. Subsequently, on March 27, 2025, BioNTech entered into a Settlement Agreement with UPenn, agreeing to pay up to $467.0 million, consisting of $400.0 million in royalties for calendar years 2020-2023, up to $15.0 million for a three-year extension of a research alliance, and $52.0 million as a contribution to a joint research and development investment fund ²⁶.

The filing does not provide specific revenue, margin, or EPS guidance for the upcoming period.

BioNTech's growth strategy includes investing in its own drug and target discovery efforts, exploring potential collaborations for new product development, and in-licensing technologies ²⁷. A key element of this strategy is to discover, develop, and potentially commercialize additional products beyond its current portfolio across various therapeutic areas ²⁸. The company plans to continue to invest heavily in research and development to build out its global development organization and diversify its therapeutic area footprint ²⁹. This includes enhancing capabilities through complementary acquisitions, technologies, infrastructure, and manufacturing ³⁰.

Operationally, BioNTech anticipates incurring significant and increasing operating expenses for the foreseeable future, particularly in research and development ³¹. The company plans to continue, expand, or modify the research and development of its preclinical programs and the scope of clinical trials for its product candidates ³². It also intends to initiate additional preclinical, clinical, or other trials for its product candidates, including under collaboration agreements ³³. BioNTech aims to continue investing in its immunotherapy platforms to identify novel technologies ³⁴. The company's manufacturing capacity and capability may change, and it may add additional suppliers ³⁵. BioNTech also plans to make changes to its infrastructure related to quality control, quality assurance, legal, compliance, and other groups to support its operations as a public company and its product development and commercialization efforts, including changes to its global sites ³⁶.

Planned capital allocation includes continued significant investment in research and development ³⁷. The company's future funding requirements will depend on factors such as the initiation, progress, timing, costs, and results of preclinical and clinical trials, the amount and timing of revenues from COVID-19 vaccine sales, and the cost of filing, prosecuting, obtaining, maintaining, protecting, defending, and enforcing its intellectual property rights ³⁸. BioNTech's capital allocation strategy also considers the cost and timing of completion and further expansion of clinical and commercial scale manufacturing activities, including the development of modular production and clinical facilities via its BioNTainer network ³⁹. The company expects to finance future cash needs through a combination of product sales, public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing or distribution arrangements ⁴⁰.

Management has explicitly flagged several structural headwinds and execution risks to the growth plan. Demand for the COVID-19 vaccine is expected to continue to decrease in the near future, impacting revenue which currently depends heavily on these sales ⁴¹. Changing market dynamics, including government policy and public sentiment, will also affect revenue and pose challenges to production ⁴². The company's reported revenue is partially based on preliminary estimates from Pfizer that are likely to change, potentially impacting reported financial results ⁴³. BioNTech may be unsuccessful in adapting its COVID-19 vaccine or developing future versions to protect against variants, and a market for such vaccines may not develop ⁴⁴. Geopolitical uncertainties, including prolonged or expanded conflicts and political responses to global actions, could destabilize oil and gas supply and demand, increase energy volatility, and severely affect regional and global supply chains and economies ⁴⁵. Trade and tariff policies among the United States and other countries are unsettled and subject to frequent changes, potentially increasing costs and adversely affecting commercial sales ⁴⁶.

BioNTech's business is subject to various material risks, including the dependence on successful development, regulatory approval, and commercialization of new medicinal product candidates, particularly oncology assets like BNT327 and antibody-drug conjugate (ADC) clinical assets ⁴⁷. The company operates in an environment of rapid technological and scientific change, including evolving standards of care, and faces intense competition from companies with significantly greater resources ⁴⁸. Product candidates may not work as intended, cause undesirable effects, or have properties that delay or prevent regulatory approval, limit commercial profiles, or result in negative consequences post-approval ⁴⁹. Clinical development is a lengthy, expensive, and uncertain process, with potential delays due to various factors, including difficulties in patient recruitment ⁵⁰. Demand for the COVID-19 vaccine is expected to decrease, impacting revenue heavily reliant on these sales, and leading to challenges in production ⁵¹. Reported revenue is based on preliminary estimates from Pfizer, which are subject to change ⁵². Other companies may challenge BioNTech's intellectual property rights or assert their own, preventing development and commercialization of the COVID-19 vaccine or product candidates ⁵³. Even if approved, products may not gain market acceptance among physicians, patients, hospitals, and the medical community ⁵⁴. Operating results may fluctuate significantly, making future predictions difficult ⁵⁵. Material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting or fraud ⁵⁶. As a "foreign private issuer," BioNTech is exempt from certain U.S. securities and Nasdaq rules, potentially limiting information for investors ⁵⁷. Manufacturing of novel technology products can be complex, leading to difficulties in production, product release, shelf life, testing, storage, supply chain management, or shipping ⁵⁸. Inadequate intellectual property protection could hinder effective competition ⁵⁹. The company has experienced, and may continue to experience, significant volatility in the market price of its ADSs ⁶⁰. Principal shareholders and management own a significant percentage of ordinary shares, exerting substantial control ⁶¹. Catastrophic global events, including natural disasters, political crises, or public health epidemics, could adversely affect operations ⁶². Product liability lawsuits, including existing claims related to the COVID-19 vaccine, could result in substantial liabilities ⁶³. Issues in the development and use of AI, coupled with an uncertain regulatory environment, may lead to reputational harm or liability ⁶⁴. The company faces risks related to ESG matters, including climate change and human rights, which could impose unexpected costs or reputational harm ⁶⁵. Adverse developments affecting financial institutions could impact operations and liquidity ⁶⁶.

Management's message to shareholders emphasizes a strong drive to build out a global development organization and diversify the therapeutic area footprint, alongside enhancing capabilities through complementary acquisitions, technologies, infrastructure, and manufacturing ⁶⁷. The company plans to continue to invest heavily in research and development ⁶⁸. Strategic priorities include continuing, expanding, or modifying the research and development of preclinical programs and the scope of clinical trials for product candidates, initiating additional trials, and investing in immunotherapy platforms to identify novel technologies ⁶⁹. Management also highlights the need to manage anticipated development and expansion, including implementing and improving managerial, operational, legal, compliance, and financial systems, expanding facilities, and recruiting and training additional qualified personnel ⁷⁰. The company expects to incur significant and increasing operating expenses for the foreseeable future ⁷¹.